Robert Blanks
General Counsel bei ARDELYX, INC.
Vermögen: 3 Mio $ am 31.03.2024
Profil
Robert C.
Blanks is the founder of Phaedrus Pharmaceuticals, which was founded in 1999.
He held the title of Vice President-Technical Operations from 1999 to 2003.
Mr. Blanks's current job is as Chief Regulatory Affairs Officer at Ardelyx, Inc., starting in 2013.
Mr. Blanks's former jobs include being a Senior Director-Quality Affairs at GelTex Pharmaceuticals, Inc., a Vice President-Quality at Idenix Pharmaceuticals LLC from 2006 to 2009, a Vice President-Chemistry, Manufacturing & Control at Flexion Therapeutics, Inc. from 2009 to 2012, and a Vice President-Operations at Trine Pharmaceuticals, Inc. from 2003 to 2008.
Mr. Blanks's education includes a graduate degree from Boston College and an undergraduate degree from Bowdoin College.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
ARDELYX, INC.
0,16% | 15.03.2024 | 367 186 ( 0,16% ) | 3 Mio $ | 31.03.2024 |
Aktive Positionen von Robert Blanks
Unternehmen | Position | Beginn |
---|---|---|
ARDELYX, INC. | General Counsel | 01.08.2013 |
Ehemalige bekannte Positionen von Robert Blanks
Unternehmen | Position | Ende |
---|---|---|
FLEXION THERAPEUTICS, INC. | Corporate Officer/Principal | 01.11.2012 |
IDENIX PHARMACEUTICALS INC | Corporate Officer/Principal | 01.08.2009 |
Trine Pharmaceuticals, Inc.
Trine Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Trine Pharmaceuticals, Inc. develops and markets pharmaceutical products. It develops drugs which are used in the areas of renal, gastrointestinal and metabolic diseases. The company is headquartered in Waltham, MA. | Corporate Officer/Principal | 19.09.2008 |
Phaedrus Pharmaceuticals | Founder | 01.03.2003 |
GelTex Pharmaceuticals, Inc.
GelTex Pharmaceuticals, Inc. BiotechnologyHealth Technology GelTex Pharmaceuticals, Inc. was developed non-absorbed, polymer-based pharmaceuticals that selectively bind and eliminate target substances from the intestinal tract. The company is a subsidiary of Geltex Corp. GelTex Pharmaceuticals was founded by Henry E Blair & James B Tananbaum in 1991 and was located in Waltham, MA. | Corporate Officer/Principal | - |
Ausbildung von Robert Blanks
Boston College | Graduate Degree |
Bowdoin College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ARDELYX, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
GelTex Pharmaceuticals, Inc.
GelTex Pharmaceuticals, Inc. BiotechnologyHealth Technology GelTex Pharmaceuticals, Inc. was developed non-absorbed, polymer-based pharmaceuticals that selectively bind and eliminate target substances from the intestinal tract. The company is a subsidiary of Geltex Corp. GelTex Pharmaceuticals was founded by Henry E Blair & James B Tananbaum in 1991 and was located in Waltham, MA. | Health Technology |
Idenix Pharmaceuticals LLC
Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
Trine Pharmaceuticals, Inc.
Trine Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Trine Pharmaceuticals, Inc. develops and markets pharmaceutical products. It develops drugs which are used in the areas of renal, gastrointestinal and metabolic diseases. The company is headquartered in Waltham, MA. | Health Technology |
Phaedrus Pharmaceuticals |